Clinical Trial Update: Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD) [Phase 3]

View source ↗

Summary

Open-label extension study of intravitreal aflibercept (EYLEA) in neovascular age-related macular degeneration completed; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2015-03-23